Abstract 303P
Background
Mandibulectomy typically involves rigid reconstruction using autologous bone and titanium plates. However, in cases with poor performance status or complications as well as the elderly, choosing the optimal surgical method is difficult. For such cases in our hospital, we do not perform rigid reconstruction but opt for only soft tissue reconstruction or primary suturing at the defect site. Here, we retrospectively investigated cases where primary suturing was applied and discuss the utility of the procedure.
Methods
This retrospective study targeted cases of stage T4 lower gingival carcinoma treated with segmental mandibulectomy and primary suturing at the defect site between 1992 and 2018. Survey items were operative time, blood loss volume, perioperative complications, length of hospitalization, and food intake at discharge.
Results
There were 186 cases for which segmental mandibulectomy was performed during the target period, and 13 cases for which primary suturing was also performed. Median operative time was 210 (range, 124-328) min. Median blood loss was 212 (101-867) mL. Six cases had complications during the perioperative period, but in all cases cure was achieved by conservative treatment. Median length of hospitalization was 32 (20-49) days. All cases could tolerate oral intake at discharge.
Conclusions
Segmental mandibulectomy without reconstruction may be a viable surgical option for cases where free tissue reconstruction is not possible.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract